Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Schizophrenia Research
|
July 5, 2021
Toxoplasma gondii, Herpesviridae and long-term risk of transition to first-episode psychosis in an ultra high-risk sample
E Burkhardt, M Berger, R H Yolken, et al.
Translational Psychiatry
|
September 21, 2016
Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers
S R Clark, B T Baune, K O Schubert, et al.
Psychological Medicine
|
August 23, 2011
Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years
M Álvarez-Jiménez, J F Gleeson, L P Henry, et al.
Neuroscience and Biobehavioral Reviews
|
October 12, 2010
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors
M Berk, F Kapczinski, A C Andreazza, et al.
Translational Psychiatry
|
May 2, 2013
Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis
C A Bousman, A R Yung, C Pantelis, et al.
Molecular Psychiatry
|
March 13, 2013
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis
S Smesny, B Milleit, U-C Hipler, et al.
The Lancet. Psychiatry
|
December 24, 2019
Evidence for preventive treatments in young patients at clinical high risk of psychosis: the need for context
Barnaby Nelson, Günter P Amminger, Andreas Bechdolf, et al.
Trials
|
November 30, 2019
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
S M Cotton, M Berk, A Watson, et al.
Current Pharmaceutical Design
|
January 14, 2012
Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder
A Bechdolf, A Ratheesh, S J Wood, et al.
Translational Psychiatry
|
August 30, 2017
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia
M A Di Biase, A Zalesky, G O'keefe, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Schizophrenia Research
|
July 5, 2021
Toxoplasma gondii, Herpesviridae and long-term risk of transition to first-episode psychosis in an ultra high-risk sample
E Burkhardt, M Berger, R H Yolken, et al.
Translational Psychiatry
|
September 21, 2016
Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers
S R Clark, B T Baune, K O Schubert, et al.
Psychological Medicine
|
August 23, 2011
Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years
M Álvarez-Jiménez, J F Gleeson, L P Henry, et al.
Neuroscience and Biobehavioral Reviews
|
October 12, 2010
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors
M Berk, F Kapczinski, A C Andreazza, et al.
Translational Psychiatry
|
May 2, 2013
Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis
C A Bousman, A R Yung, C Pantelis, et al.
Molecular Psychiatry
|
March 13, 2013
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis
S Smesny, B Milleit, U-C Hipler, et al.
The Lancet. Psychiatry
|
December 24, 2019
Evidence for preventive treatments in young patients at clinical high risk of psychosis: the need for context
Barnaby Nelson, Günter P Amminger, Andreas Bechdolf, et al.
Trials
|
November 30, 2019
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
S M Cotton, M Berk, A Watson, et al.
Current Pharmaceutical Design
|
January 14, 2012
Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder
A Bechdolf, A Ratheesh, S J Wood, et al.
Translational Psychiatry
|
August 30, 2017
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia
M A Di Biase, A Zalesky, G O'keefe, et al.
Page
of 5